Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
暂无分享,去创建一个
E. Braunwald | C. Cannon | F. Van de Werf | E. Braunwald | E. Bluhmki | C. McCabe | N. Fox | A. Luyten | K. Houbracken | S. Berioli | H. Sarelin | F. Wang-Clow | N. Fox | C. Mccabe | C. Mccabe
[1] R. Giugliano,et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.
[2] F. Werf. A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction , 1998 .
[3] T. Investigators,et al. A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .
[4] E. Braunwald,et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.
[5] W. V. Mieghem. A comparison of continuous infusion of alteplase with double bolus administration for acute myocardial infarction: the continuous infusion versus double double bolus administration of alteplase , 1997 .
[6] F. Verheugt. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. , 1997, The New England journal of medicine.
[7] R. Califf,et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. , 1995, Circulation.
[8] B. Keyt,et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. , 1995, Circulation.
[9] L. Barrios,et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. , 1995, Circulation.
[10] D. Botstein,et al. A faster-acting and more potent form of tissue plasminogen activator. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[11] Johan Herlitz,et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .
[12] B. Keyt,et al. A Slow Clearing, Fibrin-Specific, PAI-1 Resistant Variant of t-PA (T103N, KHRR 296-299 AAAA) , 1993, Thrombosis and Haemostasis.
[13] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.